Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01867437 | Effects of RM-493 on Energy Expenditure in Obese Individuals | PHASE1 | COMPLETED | 15 | — | — | May 1, 2013 | Mar 1, 2014 | Apr 20, 2017 | 1 | United States |
| Arm | Type | Description |
|---|---|---|
| RM-493 | ACTIVE_COMPARATOR | Double blind RM-493 will be administered at a dose of 1 mg/24 hrs via subcutaneous infusion for 3 days |
| Placebo | PLACEBO_COMPARATOR | Double blind placebo will be administered via subcutaneous infusion for 3 days |
| Name | Type | Description |
|---|---|---|
| Placebo | DRUG | Sterile solution (vehicle) for subcutaneous infusion |
| RM-493 | DRUG | Sterile solution (2mg/ml) for subcutaneous infusion |
* INCLUSION CRITERIA: Male and female subjects aged 18 to 50 years at screening who meet the following inclusion and exclusion criteria will be eligible for enrollment: * Able to provide written informed consent prior to any study procedures, and be willing and able to comply with study procedures...